Apyx Medical Corporation APYX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -25.71%
- 1 year
- -11.86%
- Open
- 2.65
- Prev close
- 2.69
- Mkt cap
- 109.52M
- Vol
- 38.09K
- Avg vol
- 143.17K
- EPS
- -0.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.53
- High
- 2.65
- Forward P/E
- -3.39
- Beta
- 1.21
- Short ratio
- 5.49
- Inst. own
- 40.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.41
- 200-d avg
- 1.39
- 1y target
- 2.83
Key statistics
- Market cap
- 66.40M
- Enterprise value
- 48.47M
- Trailing P/E
- 0.00
- Forward P/E
- -3.39
- PEG ratio
- 0.00
- Price / sales
- 1.35
- Price / book
- 2.29
- EPS (TTM)
- -0.82
- Beta
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -57.86%
- Revenue (TTM)
- 49.03M
- Revenue growth
- -10.50%
- Free cash flow
- 3.78M
- Total cash
- 32.68M
- Total debt
- 38.70M
- Return on equity
- -110.25%
- Shares outstanding
- 37.64M
- Short % of float
- 0.73%
- 50-day average
- 1.41
- 200-day average
- 1.39
Analyst view
Consensus: none
- Target (low)
- 2.00
- Target (mean)
- 2.83
- Target (high)
- 4.00
- Strong buy0
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.1625.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.15 | -0.14 | +0.01 | +6.67% |
| Aug 8, 2024 | Jun 1, 2024 | -0.18 | -0.19 | -0.01 | -5.56% |
| May 9, 2024 | Mar 1, 2024 | -0.18 | -0.22 | -0.04 | -22.22% |
| Mar 21, 2024 | Dec 1, 2023 | -0.13 | -0.19 | -0.06 | -46.15% |
| Nov 9, 2023 | Sep 1, 2023 | -0.10 | -0.13 | -0.03 | -30.00% |
| Aug 10, 2023 | Jun 1, 2023 | -0.12 | -0.11 | +0.01 | +8.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2024 | BTIG | init | — | Neutral |
| Sep 16, 2024 | JMP Securities | reit | — | Market Perform |
| Nov 10, 2023 | Stephens & Co. | main | Overweight | Overweight |
| Aug 11, 2023 | Piper Sandler | main | Overweight | Overweight |
| Jul 14, 2023 | Stephens & Co. | init | — | Overweight |
| Jun 15, 2023 | Lake Street | main | — | Buy |
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- apyxmedical.com
News
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)
- Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
- Apyx Medical Corporation to Participate in Upcoming Investor Conferences
- Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
- Apyx Medical Corporation (NASDAQ:APYX) Receives $6.60 Consensus Target Price from Brokerages
- Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
- Apyx Medical Q2 Earnings Call Highlights
- Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate
Your note
Sign in to keep a note on APYX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GERAGHTY MICHAEL E | Director | Conversion of Exercise of derivative security | Jun 5, 2023 | 27,500 |
| GOODWIN CHARLES D II | Chief Executive Officer | Purchase | Nov 13, 2023 | 90,000 |
| HILL MATTHEW C | Chief Financial Officer | Purchase | Aug 12, 2024 | 7,836 |
| HORNSBY TODD | Officer | Conversion of Exercise of derivative security | Jun 25, 2023 | 40 |
| WALDMAN LAWRENCE J | Director | Conversion of Exercise of derivative security | Jul 11, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Archon Capital Management LLC | 8.28% | 3,115,281 | 5.49M | Sep 29, 2024 |
| Royce & Associates LP | 6.86% | 2,582,490 | 4.55M | Sep 29, 2024 |
| Vanguard Group Inc | 3.93% | 1,480,884 | 2.61M | Sep 29, 2024 |
| Horizon Kinetics Asset Management LLC | 1.63% | 615,000 | 1.08M | Sep 29, 2024 |
| Taylor Frigon Capital Management LLC | 1.59% | 596,876 | 1.05M | Sep 29, 2024 |
| Silverberg Bernstein Capital Management LLC | 1.52% | 572,632 | 1.01M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.70% | 1,015,930 | 1.79M | Sep 29, 2024 |
| Royce Small-Cap Opportunity Fund | 2.67% | 1,003,739 | 1.77M | Sep 29, 2024 |
| Royce Micro-Cap Fund | 1.63% | 615,218 | 1.09M | Sep 29, 2024 |
| RENN Fund, Inc. | 1.63% | 615,000 | 1.08M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.10% | 414,663 | 731.38K | Sep 29, 2024 |
| Royce Capital Fund-Micro-Cap Portfolio | 0.72% | 270,273 | 476.71K | Sep 29, 2024 |